Label Changes for:
Kaletra (lopinavir and ritonavir) Solution for Oral Use
October 2008
Changes have been made to the PRECAUTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- October 2008
| The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary. Read about the new physician labeling format. |
Sections Modified
DRUG INTERACTIONS
- Established and Other Potentially Significant Drug Interactions
- Table 9: Established and Other Potentially Significant Drug Interactions
- Non-nucleoside Reverse Transcriptase Inhibitors
- Efavirenz
- HIV CCR5 – antagonist
- Maraviroc
- Anticancer Agents
- Vincristine
- Vinblastine
- Anticonvulsants
- Phenytoin
- Antidepressant
- Bupropion
- Antifungals
- Voriconazole
- Non-nucleoside Reverse Transcriptase Inhibitors
- Table 9: Established and Other Potentially Significant Drug Interactions
